bone metastases

bone metastases

Cancer that has spread from a primary tumour to the bone marrow; in descending order of frequency, bone mets originate from: breast, prostate, lung, colon, stomach, bladder, uterus, rectum, thyroid, kidney.

Clinical findings
Bone pain, soft-tissue swelling or a pathologic fracture after minor or no reportable trauma. Chronic and severe pain, spinal epidural compression leading to spinal cord compression and bone marrow failure are complications of bone metastases that can drastically reduce the patient's quality of life and life expectancy.
 
DiffDx
• Osteolytic metastases—Osteoarthritis (subchondral cysts, Schmorl nodes), metabolic bone disease, cystic angiomatosis and infiltrative bone marrow lesions.
• Sclerotic metastases—Bone islands, tuberous sclerosis, mastocytosis or osteopoikilosis.

bone metastases

Oncology Cancer that has spread from a primary tumor to the bone
References in periodicals archive ?
Amgen's sBLA for XGEVA (denosumab) to expand the currently approved indication for the prevention of skeletal-related events in patients with bone metastases from solid tumors, has been approved to include multiple myeloma.
Bone metastases represent the most frequent indication for palliative radiotherapy (RT) in these patients.
Bone metastases occur in most tumor types but are most prevalent in cancers of the breast, prostate, and lung.
Metastatic cancer is commonly found in bone, (1) and breast cancer is the most common primary tumor type in patients with bone metastases.
Key Words: Bone metastases, cancer-induced bone disease, cancer therapy induced bone loss, skeletal-related event (SRE), bisphosphonates, RANK ligand inhibitors, zoledronic acid, denosumab, hypocalcemia, osteonecrosis of the jaw, skeletal health.
lacovelli and colleagues have published an important analysis examining the role of bone metastases in prognosis and prediction of efficacy in the third-line setting.
MRI of the lumbar spine demonstrated several bone metastases (Figure 3).
Bone Cancer: Primary Bone Cancer and Bone Metastases, 2nd Edition
Biotechnology company Exelixis Inc (NasdaqGS :EXEL) reported on Monday the start of a phase 2 clinical trial comparing cabozantinib plus abiraterone and prednisone (abiraterone/prednisone) versus abiraterone/prednisone in patients with bone metastases castration-resistant prostate cancer (CRPC).
Prostate cancer cells have an exquisite tropism for bone, which clinically translates into the highest rate of bone metastases amongst male cancers.
In patients with DTC complicated with bone metastases, treatment modalities should include total thyroidectomy, metastasectomy -if possible-, RAI therapy, and external radiation therapy (8).
Algeta ASA has announced that the US Food and Drug Administration (FDA) has approved Xofigo (radium-223 dichloride) injection for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease.